Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | RXRA | P19793 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | CES2 | O00748 | 1/20 | 0.35 |
| ▸ | MET | P08581 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | PPARA | Q07869 | 1/20 | 0.34 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28014227 | 0.87 | ALDH1A1 (0.37) | HPGDCYP1A2CYP3A4CYP2C19RXRA | |
| SCHEMBL592368 | 0.79 | ATM (0.44) | ALDH1A1HTT | |
| SCHEMBL1316259 | 0.79 | LMNA (0.51) | HPGDCYP1A2CYP3A4CYP2C19LMNA | |
| SCHEMBL1317836 | 0.79 | ABCB1 (0.39) | ALDH1A1GAAMETVCAM1SMN1; SMN2 | |
| SCHEMBL12980667 | 0.78 | MAPT (0.46) | HPGDALDH1A1HTTLMNAVCAM1 | |
| SCHEMBL3512823 | 0.78 | CASP6 (0.55) | HPGDLMNAGAA | |
| SCHEMBL1186377 | 0.77 | ALDH1A1 (0.45) | HPGDALDH1A1HTTLMNAVCAM1 | |
| SCHEMBL1374342 | 0.77 | MAPT (0.50) | LMNASMN1; SMN2 | |
| SCHEMBL2721807 | 0.77 | VCAM1 (0.59) | HPGDALDH1A1LMNAGAAVCAM1 | |
| SCHEMBL3654154 | 0.76 | KMT2A (0.45) | HPGDCYP1A2CYP3A4CYP2C19ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2518056-B1 | SEVEN-MEMBERED RING COMPOUND AND PHARMACEUTICAL USE THEREFOR | DAIICHI SANKYO CO LTD (JP) | 2015-07-29 | — | — | EP | disclosed |
| US-8846660-B2 | Seven-membered ring compound and pharmaceutical use therefor | DAIICHI SANKYO COMPANY, LTD. (JP) | 2014-09-30 | — | — | US | disclosed |
| EP-2518056-A1 | SEVEN-MEMBERED RING COMPOUND AND PHARMACEUTICAL USE THEREFOR | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-10-31 | — | — | EP | disclosed |
| US-20120259111-A1 | SEVEN-MEMBERED RING COMPOUND AND PHARMACEUTICAL USE THEREFOR | DAIICHI SANKYO COMPANY LIMITED (JP) | 2012-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120259111-A1 | SEVEN-MEMBERED RING COMPOUND AND PHARMACEUTICAL USE THEREFOR | CMA1, CPA3, TMPRSS15 | HPGD 296/4885CYP1A2 1377/4885CYP3A4 1013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.